Log in to save to my catalogue

AZD9291 in

AZD9291 in

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_futurescience_futuremedicine_10_2217_fon_15_250

AZD9291 in

About this item

Full title

AZD9291 in

Author / Creator

Publisher

Future Medicine Ltd

Journal title

Future oncology (London, England), 2015-11, Vol.11 (22), p.3069-3081

Language

English

Formats

Publication information

Publisher

Future Medicine Ltd

More information

Scope and Contents

Contents

Non-small-cell lung cancer (NSCLC) patients whose tumors have an
-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. T790M mutation is the cause of this resistance in approximately 60% of cases. AZD9291 is an oral, irreversible, mutant-selective EG...

Alternative Titles

Full title

AZD9291 in

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_futurescience_futuremedicine_10_2217_fon_15_250

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_futurescience_futuremedicine_10_2217_fon_15_250

Other Identifiers

ISSN

1479-6694

E-ISSN

1744-8301

DOI

10.2217/fon.15.250

How to access this item